by Madaline Spencer | Feb 5, 2025
Emma Searle, PhD, The Christie NHS Foundation Trust and University of Manchester, discusses bleximenib in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). AML is a group of neoplasms arising from precursor cells...
by Madaline Spencer | Feb 4, 2025
Carolina Schinke, MD, University of Arkansas for Medical Sciences, discusses differences in clinical outcomes of black patients with multiple myeloma treated with talquetamab. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by...
by Madaline Spencer | Feb 3, 2025
Christopher Patriquin, MD, University of Toronto, discusses results of a clinical trial comparing combination C5 inhibitor therapy versus standard of care in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare clonal hematopoietic stem...
by Madaline Spencer | Jan 30, 2025
Elias Mai, MD, Heidelberg Myeloma Center, discusses the GMMG-HD7 clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic...
by Madaline Spencer | Jan 28, 2025
Pieter Sonneveld, MD, Erasmus MC Cancer Institute, discusses results from the PERSEUS clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal...
